Horizon: New Long-Term Data for UPLIZNA for Neuromyelitis Optica Spectrum Disorder

 -- Presentation at American Academy of Neurology’s 73rd Annual Meeting shows no new safety signals with prolonged use of UPLIZNA --

-- UPLIZNA continues to lower the rate of NMOSD attacks throughout the four-year open-label period (OLP) --

-- Results from NMOSD patient survey describe long and daunting journey to diagnosis --

https://finance.yahoo.com/news/long-term-data-uplizna-inebilizumab-123000650.html